Neuroendocrine Studies in Huntington’s Disease

  • Raymon Durso
  • Stefano A. Ruggieri
  • Alessandro Denaro
  • Carol A. Tamminga


During the past 15 years, the neuroendocrine system has been studied in Huntington’s disease (HD) for the purpose of examining underlying hormonal and neurotransmitter abnormalities within the hypothalamic-pituitary axis. Although a clinically overt endocrinopathy has not been described, symptoms of progressive weight loss, disturbances in sweating, and reports of increased fertility in HD women have indeed been observed (Reed and Neel, 1959; Bruyn, 1968; Marx, 1973), and suggest hypothalamic dysfunction in affected individuals. Moreover, postmortem studies of the hypothalamus in HD patients have demonstrated a number of pathological findings including atrophy associated with neuronal cell loss (Vogt and Vogt, 1952; Bruyn, 1973) and alterations in monoamine metabolites (Bernheimer and Hornykiewicz, 1973).


Growth Hormone Growth Hormone Secretion Prolactin Secretion Growth Hormone Release Prolactin Release 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Andén, N. E., and Wachtel, H., 1977, Biochemical effects of baclofen (beta-parachlorophenyl-GABA) on the dopamine and the noradrenaline in the rat brain, Acta Pharmacol. Toxicol.:opKbh.) 40:310.CrossRefGoogle Scholar
  2. Bernheimer, H., and Hornykiewicz, O., 1973, Brain amines in Huntington’s chorea, in: Advances in Neurology, Vol. 1, Huntington’s Chorea 1872–1972 (A. Barbeau, T. N. Chase, and G. W. Paulson, eds.), pp. 525–531, Raven Press, New York.Google Scholar
  3. Besses, G. S., Burrow, G. N., Spaulding, S. W., and Donabedion, R. K., 1975, Dopamine infusion acutely inhibits the TSH and prolactin response to TRH, J. Clin. Endocrinol. Metab. 41:985.PubMedCrossRefGoogle Scholar
  4. Bird, E. D., Chiappa, S. A., and Fink, G., 1976, Brain immunoreactive gonadotropin-releasing hormone in Huntington’s chorea and non-choreic subjects, Nature (London) 260:536.CrossRefGoogle Scholar
  5. Birge, C. A., Jacobs, L. S., Hammer, C. T., and Daughaday, W. H., 1970, Catecholamine inhibition of prolactin secretion by isolated rat adenohypophyses, Endocrinology 86:120.PubMedCrossRefGoogle Scholar
  6. Blackard, W. G., and Waddell, C. C., 1969, Cholinergic blockade and growth hormone responsiveness to insulin hypoglycemia, Proc. Soc. Exp. Biol. Med. 131:192.PubMedGoogle Scholar
  7. Brown, G. M., and Reichlin, S., 1972, Psychologic and neural regulation of growth hormone secretion, Psychosom. Med. 34:45.PubMedGoogle Scholar
  8. Brown, G. M., Seeman, P., and Lee, T., 1976, Dopamine/neuroleptic receptors in basal hypothalamus and pituitary, Endocrinology 99:1407.PubMedCrossRefGoogle Scholar
  9. Brown, W. A., Von Woert, M. H., and Ambani, L. M., 1973, Effect of apomorphine on growth hormone release in humans, J. Clin. Endocrinol. Metab. 37:463.PubMedCrossRefGoogle Scholar
  10. Brownstein, M., Arimura, A., Sato, H., Serially, A. V., and Kizer, J. S., 1975, The regional distribution of somatostatin in the rat brain, Endocrinology 96:1456.PubMedCrossRefGoogle Scholar
  11. Bruyn, G. W., 1968, Huntington’s chorea, historical, clinical, and laboratory synopsis, in: Handbook of Clinical Neurology, Vol. 6, Diseases of the Basal Ganglia (P. J. Vinken and G. W. Bruyn, eds.), pp. 298–378, North-Holland, Amsterdam.Google Scholar
  12. Bruyn, G. W., 1973, Neuropathological changes in Huntington’s chorea, in: Advances in Neurology, Vol. 1, Huntington’s Chorea 1872–1972 (A. Barbeau, T. N. Chase, and G. W. Paulson, eds.), pp. 399–403, Raven Press, New York.Google Scholar
  13. Caine, E., Kartzinel, R., Ebert, M., and Carter, A. C., 1978, Neuroendocrine function in Huntington’s disease: Dopaminergic regulation of prolactin release, Life Sci. 22:911.PubMedCrossRefGoogle Scholar
  14. Camanni, F., Massara, F., Belforte, L., and Molinatti, G. M., 1975, Changes in plasma growth hormone levels in normal and acromegalic subjects following administration of 2-bromo-α-ergocryptine, J. Clin. Endocrinol. Metab. 40:363.PubMedCrossRefGoogle Scholar
  15. Caraceni, T., Panerai, A. E., Parat, E. A., Coechi, D., and Muller, E. E., 1977, Altered growth hormone and prolactin responses to dopaminergic stimulation in Huntington’s chorea, J. Clin. Endocrinol. Metab. 44:870.PubMedCrossRefGoogle Scholar
  16. Caron, M., Raymond, V., Lefkowitz, R., and Labrie, F., 1977, Identification of dopaminergic receptors in anterior pituitary: Correlation with the dopaminergic control of prolactin release, Fed. Proc. 36:278.Google Scholar
  17. Casaneuva, F., Betti, R., Frigerio, C., Cocchi, D., Mantegazza, P., and Müller, E. E., 1980, Growth hormone-releasing effect of an enkephalin analog in the dog: Evidence for cholinergic mediation, Endocrinology 106:1239.CrossRefGoogle Scholar
  18. Cavagnini, F., Invitti, C., Di Landro, A., Tenconi, L., Maraschini, C., and Girotti, G., 1977, Effects of gamma-aminobutyric acid (GABA) derivative, baclofen, on growth hormone and prolactin secretion in man, J. Clin. Endocrinol. Metab. 45:579.PubMedCrossRefGoogle Scholar
  19. Chalmers, R. J., Johnson, R. H., Keogh, H. J., and Nanda, R. N., 1978, Growth hormone and prolactin response to bromocriptine in patients with Huntington’s chorea, J. Neurol. Neu-rosurg. Psychiatry 41:135.CrossRefGoogle Scholar
  20. Chambers, J. W., and Brown, G. M., 1976, Neurotransmitter regulation of growth hormone and ACTH in the rhesus monkey: Effects on biogenic amines, Endocrinology 98:420.PubMedCrossRefGoogle Scholar
  21. Cheung, C. Y., and Weiner, R. I., 1976, Supersensitivity of anterior pituitary dopamine receptors involved in the inhibition of prolactin secretion following destruction of the medial basal hypothalamus, Endocrinology 99:914.PubMedCrossRefGoogle Scholar
  22. Chihara, K., Arimura, A., Chihara, M., and Schally, A. V., 1978, Studies on the mechanism of growth hormone and thyrotropin responses to somatostatin antiserum in anesthetized rats, Endocrinology 103:1916.PubMedCrossRefGoogle Scholar
  23. Clemens, J. A., Smalstig, E. G., and Shaar, C. J., 1975, Inhibition of prolactin secretion by lergotrile mesylate: Mechanism of action, Acta Endocrinol. (Kbh) 79:230.PubMedGoogle Scholar
  24. Clow, A., Theodorou, A., Jenner, P., and Marsden, C. D., 1980, Changes in cerebral dopamine function induced by a year’s administration of trifluoperazine or thioridazine and their subsequent withdrawal, in: Advances in Biochemical Psychopharmacology, Vol. 24, Long-term Effects of Neuroleptics (F. Cattabeni, P. F. Spano, G. Racagni, and E. Costa, eds.), pp. 335–340, Raven Press, New York.Google Scholar
  25. Cooper, P. E., Aronin, N., Bird, E. D., Leeman, S. E., and Martin, J. B., 1981, Increased somatostatin in basal ganglia of Huntington’s disease, Neurology 31:64 (abstract).Google Scholar
  26. Cramer, H., Kohler, J., Oepen, G., Schomburg, G., and Schroter, E., 1981, Huntington’s chorea— Measurements of somatostatin, substance P and cyclic nucleotides in the cerebrospinal fluid, J. Neurol. 225:183.PubMedCrossRefGoogle Scholar
  27. Drouin, J., De Léan, A., Rainville, D., LaChance, R., and Labrie, F., 1976, Characteristics of the interaction between thyrotropin-releasing hormone and somatostatin for thyrotropin and prolactin release, Endocrinology 98:514.PubMedCrossRefGoogle Scholar
  28. Durso, R., Tamminga, C. A., Ruggieri, S., Denaro, A., Gillespie, M., and Chase, T. N., 1983a, Circadian release of growth hormone, prolactin, and luteinizing hormone in Huntington’s disease, J. Neuro. Neurosurg. Psychiatry in press.Google Scholar
  29. Durso, R., Tamminga, C. A., Ruggieri, S., Denaro, A., Gillespie, M., and Chase, T. N., 1983b, Neuroendocrine defects in Huntington’s disease, Neurology in press.Google Scholar
  30. Epelbaum, J., Brazeau, P., Tsang, D., Brawer, J., and Martin J. B., 1977, Subcellular distribution of radioimmunoassayable somatostatin in rat brain, Brain Res. 126:309.PubMedCrossRefGoogle Scholar
  31. Finkelstein, J. W., Boyar, R. M., Roffwarg, H. P., Kream, J., and Hellman, L., 1972, Age-related change in the twenty-four hour spontaneous secretion of growth hormone. J. Clin. Endocrinol. Metab. 35:665.PubMedCrossRefGoogle Scholar
  32. Frantz, A. G., and Rabkin, M. T., 1965, Effects of estrogen and sex difference on secretion of human growth hormone, J. Clin. Endocrinol. Metab. 25:1470.PubMedCrossRefGoogle Scholar
  33. Grandison, L., and Meites, J., 1976, Evidence for adrenergic mediation of cholinergic inhibition of prolactin release, Endocrinology 99:775.PubMedCrossRefGoogle Scholar
  34. Hall, R., Besser, G. M., Schally, A. V., Coy, D. H., Evered, D., Goldie, D. J., Kastin, A. J., McNeilly, A. S., Mortimer, C. H., Phenekos, C., Tunbridge, W. M. G., and Weightman, D., 1973, Action of growth-hormone-release inhibitory hormone in healthy men and in acromegaly, Lancet II:581.CrossRefGoogle Scholar
  35. Hansen, A. P., 1971, The effect of adrenergic receptor blockade on the exercise-induced serum growth hormone rise in normals and juvenile diabetics, J. Clin. Endocrinol. Metab. 33:807.PubMedCrossRefGoogle Scholar
  36. Hayden, M. R., Paul, M., Vinik, A. I., and Beighton, P., 1977, Impaired prolactin release in Huntington’s chorea: Evidence for dopaminergic excess, Lancet II:423.CrossRefGoogle Scholar
  37. Horowski, R., and Graf, H. J., 1976, Influence of dopaminergic agonists and antagonists on serum prolactin concentrations in the rat, Neuroendocrinology 22:273.PubMedCrossRefGoogle Scholar
  38. Keogh, H. J., Johnson, R. H., Nanda, R. N., and Sulaiman, W. R., 1976, Altered growth hormone release in Huntington’s chorea, J. Neurol. Neurosurg. Psychiatry 39:244.PubMedCrossRefGoogle Scholar
  39. Koulu, M., Lammintausta, R., and Dahlström, S., 1980, Effects of some gamma-aminobutyric acid (GABA)-ergic drugs on the dopaminergic control of human growth hormone secretion, J. Clin. Endocrinol. Metab. 51:124.PubMedCrossRefGoogle Scholar
  40. Lahti, R. A., and Losey, E. G., 1974, Antagonism of the effects of chlorpromazine and morphine on dopamine metabolism by GABA, Res. Commun. Chem. Pathol. Pharmacol. 7:31.PubMedGoogle Scholar
  41. Lai, S., De La Vega, C. E., Sourkes, T. L., and Friesen, H. G., 1972, Effect of apomorphine on human-growth-hormone secretion, Lancet II:661.Google Scholar
  42. Lai, S., Tolis, G., Martin, S. B., Brown, G. M., and Guyda, H., 1975, Effect of Clonidine on growth hormone, prolactin, luteinizing hormone, follicle-stimulating hormone, and thyroid-stimulating hormone in the serum of normal men, J. Clin. Endocrinol. Metab. 41:827.CrossRefGoogle Scholar
  43. Leblanc, H., Lachelin, G. C. L., Abu-Fadil, S., and Yen, S. S. C., 1976, Effects of dopamine infusion on pituitary hormone secretion in humans, J. Clin. Endocrinol. Metab. 43:668.PubMedCrossRefGoogle Scholar
  44. Leopold, N. A., and Podolsky, S., 1975, Exaggerated growth hormone response to arginine infusion in Huntington’s disease, J. Clin. Endocrinol. Metab. 41:160.PubMedCrossRefGoogle Scholar
  45. Leopold, N. A., and Podolsky, S., 1979, Levodopa and glucose influence on prolactin secretion in Huntington’s disease, in: Advances in Neurology, Vol. 23, Huntington’s Disease (T. N. Chase, N. S. Wexler, and A. Barbeau, eds.), pp. 299–304, Raven Press, New York.Google Scholar
  46. Levy, C. L., Carlson, H. F., Sowers, J. R., Goodlett, R. E., Tourtellotte, W. W., and Hershman, J. M., 1979, Growth hormone and prolactin secretion in Huntington’s disease, Life Sci. 24:743.PubMedCrossRefGoogle Scholar
  47. Liuzzi, A., Chiodini, P. G., Oppizzi, G., Botalla, L., Verde, G., DeStefano, L., Colussi, G., Gräf, K. J., and Horowski, R., 1978, Lisuride hydrogen maleate: Evidence for a long lasting dopaminergic activity in humans, J. Clin. Endocrinol. Metab. 46:196.PubMedCrossRefGoogle Scholar
  48. Locatelli, V., Cocchi, D., Frigerio, C., Betti, R., Krogsgaard-Larsen, P., Racagni, G., and Müller, E. E., 1979, Dual γ-aminobutyric acid control prolactin secretion in the rat, Endocrinology 105:778.PubMedCrossRefGoogle Scholar
  49. Lovinger, R. D., Rose, J., Boryczka, A. T., Shackelford, R., Kaplan, S. L., Ganong, W. F., and Grumbach, M. M., 1975, Effect of altered brain amine content and selective electrical stimulation in the control of growth hormone in the dog, Int. Symp. Growth Hormone Related Peptides, Milan, p. 59.Google Scholar
  50. Lovinger, R., Holland, L. Jr., Kaplan, S., Grumbach, M., Boryczka, A. T., Shackleford, R., Salmon, J., Reid, I. A., and Ganong, W. F., 1976, Pharmacological evidence for stimulation of growth hormone secretion by a central noradrenergic system in dogs, Neuroscience 1:443.PubMedCrossRefGoogle Scholar
  51. Luedecke, G., Mueller, D., and Patino, J., 1976, 5th Int. Congr. Endocrinol. (Abstract Book), Hamburg, p. 272.Google Scholar
  52. MacLeod, R. M., and Lehmeyer, J. E. 1974, Studies on the mechanism of the dopamine-mediated inhibition of prolactin secretion, Endocrinology 25:1077.CrossRefGoogle Scholar
  53. Martin, J. B., 1972, Plasma growth hormone (GH) response to hypothalamic or extrahypothalamic electrical stimulation, Endocrinology 91:107.PubMedCrossRefGoogle Scholar
  54. Martin, J. B., Durand, D., Gurd, W., Faille, G., Audet, J., and Brazeau, P., 1978, Neurophar-macological regulation of episodic growth hormone and prolactin secretion in the rat, Endocrinology 102:106.PubMedCrossRefGoogle Scholar
  55. Marx, R. N., 1973, Huntington’s chorea in Minnesota, in: Advances in Neurology, Vol. 1, Huntington’s Chorea 1872–1972 (A. Barbeau, T. N. Chase, and G. W. Paulson, eds.), p. 237, Raven Press, New York.Google Scholar
  56. Merimee, T. J., Bergess, J. A., and Rabinowitz, D., 1966, Sex-determined variation in serum insulin and growth hormone response to amino acid stimulation, J. Clin. Endocrinol. Metab. 26:791.PubMedCrossRefGoogle Scholar
  57. Müller, E. E., Dal Pra, P., and Pecile, A., 1968, Influence of brain neurohumors injected into the lateral ventricle of the rat on growth hormone release, Endocrinology 83:893.PubMedCrossRefGoogle Scholar
  58. Müller, E. E., Parati, E. A., Panerai, A. E., Cocchi, D., and Caraceni, T., 1979a, Growth hormone hyperresponsiveness to dopaminergic stimulation in Huntington’s chorea, Neuroendocrinology 28:313.PubMedCrossRefGoogle Scholar
  59. Müller, E. E., Parati, E. A., Cocchi, D., Zanardi, P., and Caraceni, T., 1979b, Dopaminergic drugs on growth hormone and prolactin secretion in Huntington’s disease, in: Advances in Neurology, Vol. 23, Huntington’s Disease (T. N. Chase, N. S. Wexler, and A. Barbeau, eds.), pp. 319–334, Raven Press, New York.Google Scholar
  60. Murri, L., Iudice, A., Muratorio, A., Pollen, A., Barreca, T., and Muriaido, G., 1980, Spontaneous nocturnal plasma prolactin and growth hormone secretion in patients with Parkinson’s disease and Huntington’s chorea, Eur. Neurol. 19:198.PubMedCrossRefGoogle Scholar
  61. Nemeroff, C. B., Konkol, R. J., Bissette, G., Youngblood, W., Martin, J. B., Brazeau, P., Rone, M. S., Prange, A. J., Breese, G. R., and Skizer, J., 1977, Analysis of the disruption in hy-pothalamic-pituitary regulation in rats treated neonatally with monosodium L-glutamate (MSG): Evidence for the involvement of tuberoinfundibular cholinergic and dopaminergic systems in neuroendocrine regulation, Endocrinology 101:613.PubMedCrossRefGoogle Scholar
  62. Nistri, A., and Constanti, A., 1975, Some observations on the mechanism of action of baclofen (beta-chlorophenyl-gamma-amino-butyric acid), Experientia 31:64.PubMedCrossRefGoogle Scholar
  63. Parker, D. C., Rossman, L. G., Siler, T. M., Rivier, J., Yen, S. S. C., and Guillemin, R., 1974, Inhibition of the sleep-related peak in physiologic human growth hormone release by somatostatin, J. Clin. Endocrinol. Metab. 38:496.PubMedCrossRefGoogle Scholar
  64. Philippu, A., Przuntek, H., and Rosenberg, W., 1973, Superfusion of the hypothalamus with gamma-aminobutyric acid: Effect on release of noradrenaline and blood pressure, Naunyn-Schmiedebergs Arch. Pharmacol. 276:103.PubMedCrossRefGoogle Scholar
  65. Phillipson, O. T., and Bird, E. D., 1976, Plasma growth hormone concentrations in Huntington’s chorea, Clin. Sci. Mol. Med. 50:551.PubMedGoogle Scholar
  66. Podolsky, S., and Leopold, N. A., 1974, Growth hormone abnormalities in Huntington’s chorea: Effect of L-dopa administration, J. Clin. Endocrinol. Metab. 39:36.PubMedCrossRefGoogle Scholar
  67. Polleri, A., Savoldi, F., Muratorio, A., Masturzo, P., Muriaido, G., Martignori, E., Nappi, G., Iudice, A., and Murri, L., 1980, Circadian rhythmicity of prolactin secretion in Huntington’s chorea, Life Sci. 26:1609.PubMedCrossRefGoogle Scholar
  68. Prang Hansen, A., Ørskov, H., Seyer-Hansen, K., and Lundbaek, K., 1973, Some actions of growth hormone release inhibiting factor, Br. Med. J. 3:523.CrossRefGoogle Scholar
  69. Reed, T. E., and Neel, J. V., 1959, Huntington’s chorea in Michigan. 2. Selection and mutation, Am. J. Hum. Genet. 11:107.PubMedGoogle Scholar
  70. Ruch, W., Mixter, R. C., Russell, R. M., Garcia, G. F., and Gale, C. C., 1977, Aminergic and thermoregulatory mechanisms in hypothalamic regulation of growth hormone in cats, Am. J. Physiol. 223:E61.Google Scholar
  71. Schally, A. V., Redding, T. W., Arimura, A., Dupont, A., and Linthicum, G. L., 1977, Isolation of gamma-aminobutyric acid from pig hypothalami and demonstration of its prolactin release-inhibiting (PIF) activity in vivo and in vitro, Endocrinology 100:681.CrossRefGoogle Scholar
  72. Siler, T. M., Vanden Berg, G., and Yen, S. S. C., 1973, Inhibition of growth hormone release in humans by somatostatin, J. Clin. Endocrinol. Metab. 37:632.PubMedCrossRefGoogle Scholar
  73. Siler, T. M., Yen, S. S. C., Vale, W., and Guillemin, R., 1974, Inhibition by somatostatin on the release of TSH induced in man by thyrotropin-releasing factor, J. Clin. Endocrinol. Metab. 38:742.PubMedCrossRefGoogle Scholar
  74. Smalstig, E. B., Sawyer, B. D., and Clemens, J. A., 1974, Inhibition of rat prolactin release by apomorphine in vivo and in vitro, Endocrinology 95:123.CrossRefGoogle Scholar
  75. Smith, R. C., and Davis, J. M., 1976, Behavioral evidence for supersensitivity after chronic administration of haloperidol, clozapine, and thioridazine, Life Sci. 19:725.PubMedCrossRefGoogle Scholar
  76. Steiner, R. A., Rolfs, A., Shen, L., Illner, P., and Gale, C. C., 1976, Neuroendocrine control of prolactin and growth hormone secretion in the baboon, Clin. Res. 24:101 (abstract).Google Scholar
  77. Steiner, R. A., Stewart, J. K., Barber, J., Koerker, D., Goodner, C. J., Brown, A., Illner, P., and Gale, C. C., 1978, Somatostatin: A physiological role in the regulation of growth hormone secretion in the adolescent male baboon, Endocrinology 102:1587.PubMedCrossRefGoogle Scholar
  78. Takahara, J., Arimura, A., and Schally, A. V., 1974, Suppression of prolactin release by a purified porcine PIF preparation and catecholamines infused into a rat hypophyseal portal vessel, Endocrinology 96:462.CrossRefGoogle Scholar
  79. Tamminga, C. A., Neophytides, A., Chase, T. N., and Frohman, L. A., 1978, Stimulation of pro-lactin and growth hormone secretion by muscimol, a 7-aminobutyric acid agonist, J. Clin.Endocrinol. M e tab. 47:1348.CrossRefGoogle Scholar
  80. Tappaz, M. L., and Brownstein, M. J., 1977, Origin of glutamate-decarboxylase (GAD)-containing cells in discrete hypothalamic nuclei, Brain Res. 132:95.PubMedCrossRefGoogle Scholar
  81. Tappaz, M. L., Brownstein, M. J., and Palkovits, M., 1976, Distribution of glutamate decarboxylase in discrete brain nuclei, Brain Res. 108:371.PubMedCrossRefGoogle Scholar
  82. Tappaz, M. L., Brownstein, M. J., and Kopin, I. J., 1977, Glutamate decarboxylase (GAD) and gamma-aminobutyric acid (GABA) in discrete nuclei of the hypothalamus and substantia nigra, Brain Res. 125:109.PubMedCrossRefGoogle Scholar
  83. Thorner, M. O., Wass, J. A. H., Jones, A., Bloom, S. R., and Macleod, R. M., 1976, 5th Int. Congr. Endocrinol. (Abstract Book), Hamburg, p. 24.Google Scholar
  84. Thorner, M. O., Ryan, S. M., Wass, J. A. H., Jones, A., Bouloux, P., Williams, S., and Besser, G. M., 1978, Effect of the dopamine agonist, lergotrile mesylate, on circulating anterior pituitary hormones in man, J. Clin. Endocrinol. Metab. 47:372.PubMedCrossRefGoogle Scholar
  85. Toivola, P. T. K., and Gale, C. C., 1972, Stimulation of growth hormone release by microinjection of norepinephrine into hypothalamus of baboons, Endocrinology 90:895.PubMedCrossRefGoogle Scholar
  86. Toivola, P. T. K., Gale, C. C., Goodner, C. J., and Werrbach, J. H., 1972, Central-adrenergic regulation of growth hormone and insulin, Hormones 3:192.PubMedCrossRefGoogle Scholar
  87. Vale, W., Rivier, C., Brazeau, P., and Guillemin, R., 1974, Effects of somatostatin on the secretion of thyrotropin and prolactin, Endocrinology 95:968.PubMedCrossRefGoogle Scholar
  88. Vijayan, E., and McCann, S. M., 1978, The effects of intraventricular injection of gamma-aminobutyric acid (GABA) on prolactin and gonadotropin release in conscious female rats, Brain Res. 155:35.PubMedCrossRefGoogle Scholar
  89. Vogt, C., and Vogt, O., 1952, Precipitating and modifying agents in chorea, J. Nerv. Ment. Dis. 116:601.PubMedCrossRefGoogle Scholar
  90. Walters, J. R., Roth, R. H., and Aghajanian, G. K., 1973, Dopaminergic neurons: Similar biochemical and histochemical effects of gamma-hydroxybutyrate and acute lesions of the nigro-neostriatal pathway, J. Pharmacol. Exp. Ther. 186:630.PubMedGoogle Scholar
  91. Yen, S. S. C., Siler, T. M., and DeVane, G. W., 1974, Effect of somatostatin in patients with acromegaly: Suppression of growth hormone, prolactin, insulin and glucose levels, N. Engl. J. Med. 290:935.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1984

Authors and Affiliations

  • Raymon Durso
    • 1
  • Stefano A. Ruggieri
    • 2
  • Alessandro Denaro
    • 2
  • Carol A. Tamminga
    • 3
  1. 1.Department of NeurologyBoston University School of MedicineBostonUSA
  2. 2.Department of NeurologyUniversity of RomeRomeItaly
  3. 3.Department of PsychiatryUniversity of MarylandBaltimoreUSA

Personalised recommendations